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Summary
Background: Chronic constipation is a common, heterogeneous disorder with multiple symptoms and pathophysiological mechanisms. Patients are often referred to a
gastroenterology provider after laxatives fail. However, there is limited knowledge of
the spectrum and management of constipation disorders.
Aim: To discuss the latest understanding of the spectrum of constipation disorders,
tools for identifying a pathophysiologic-based diagnosis in the specialist setting,
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treatment options and the patient's perspective of constipation.
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Results: Clinical assessment, stool diaries and Rome IV diagnostic criteria can fa-

Methods: Literature searches were conducted using PubMed for constipation diagnostic criteria, diagnostic tools and approved treatments. The authors provided insight from their own practices.
cilitate diagnosis, evaluate severity and distinguish between IBS with constipation,
chronic idiopathic constipation and dyssynergic defecation. Novel smartphone applications can help track constipation symptoms. Rectal examinations, anorectal manometry and balloon expulsion, assessments of neuromuscular function with colonic
transit time and colonic manometry can provide mechanistic understanding of underlying pathophysiology. Treatments include lifestyle and diet changes, biofeedback
therapy and pharmacological agents. Several classes of laxatives, as well as prokinetic
and prosecretory agents, are available; here we describe their mechanisms of action,
efficacy and side effects.
Conclusions: Constipation includes multiple overlapping subtypes identifiable using
detailed history, current diagnostic tools and smartphone applications. Recognition
of individual subtype(s) could pave the way for optimal, evidence-based treatments
by a gastroenterology provider.
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1 | I NTRO D U C TI O N

3 | PATH O PH YS I O LO G Y

Constipation affects 15%-20% of the global population and carries

The pathophysiology of constipation is multifactorial and var-

a major health care burden.1,2 The pathophysiology of chronic con-

ies between patients. Patients with primary constipation are

stipation is complex, exemplified by varying classifications. Patients

classified as having one of the three overlapping subtypes: def-

often present with similar, overlapping symptoms.

3,4

Therefore,

differentiation and appropriate classification of constipation types
guides treatment selection.

4,5

ecatory disorders, slow-t ransit constipation or normal transit
constipation. 3,4,11

Constipation is classified as primary

Defecatory disorders are often associated with underlying dys-

or secondary, depending on the underlying cause.3,4 Secondary con-

synergic defecation, characterised by impaired rectal evacuation

stipation is associated with organic disease (eg, colonic stricture,

from inadequate rectal propulsion forces, high anal resting pres-

mass or malignancy), medication use (eg, opioids, anti-cholinergic

sure and/or paradoxical contraction of the anal sphincter and pel-

medications) or an underlying condition (eg, metabolic, thyroid or

vic floor muscles during defecation or incomplete relaxation.3,4,11,12

diabetic disorders), while primary constipation is a consequence of

Dyssynergic defecation results from uncoordinated contraction of

neuromuscular dysfunction of the colon or anorectal sensory-motor

the abdominal and pelvic floor muscles.13,14 Difficulty defecating

function.

3,6

may also be compounded by anatomical abnormalities (eg, rectoce-

The complexity of primary constipation—and failure to respond to
first-line treatments (eg, lifestyle changes and laxatives)—is why pa5

les, intussusception) or altered rectal sensitivity.3,11
Primary slow colonic transit constipation can be caused by neu-

tients are referred to gastrointestinal (GI) specialists. Constipation

romuscular dysfunction of the colon wall that is not associated with

disorders are sometimes difficult to manage, and patients are often

other disorders or underlying systemic diseases.3,11 Colonic motor

7

dissatisfied with their treatment. Symptoms of constipation can be

disturbances, or myopathies, are associated with low-amplitude con-

secondary to GI pathology, such as colonic strictures, advanced col-

traction resulting in reduced propulsion and colonic stasis leading to

orectal polyps or neoplasms, necessitating an age-appropriate colon

water reabsorption and stool hardening, accompanied by a reduced

cancer screening. Failure to address constipation disorders may re-

feeling of the need to defecate.3,11 Colonic neuropathy, associated

sult in symptom progression over time.

8

with disorganised or uncoordinated contraction, may include abnor-

IBS with constipation (IBS-C), functional constipation or chronic

mal colonic sensation contributing to abdominal pain and bloating

idiopathic constipation (CIC) and defecatory disorders—especially

and altered neuromuscular signalling in and/or to the colonic wall.3,11

dyssynergic defecation—comprise the most common spectrum of

The colons of patients with chronic constipation have shown a re-

primary constipation disorders.9 IBS-C , CIC and dyssynergic def-

duced number of intrinsic nerves and interstitial cells of Cajal and a

ecation have overlapping symptoms.8 Another growing problem is

decreased response to cholinergic stimulation.3,11 Evidence suggests

opioid-induced constipation (OIC) and, although a secondary cause

that methane gas accumulation in the GI tract, or intestinal metha-

of constipation, significant new knowledge in the pathophysiology

nogenic overgrowth, is associated with reduced colonic transit and

and treatment of OIC is helpful for GI specialists to consider when

slow transit constipation15; however, a separate study presented

differentiating from a primary constipation diagnosis.10 Our purpose

conflicting data where breath methane excretion was not associated

is to provide an up-to-date review on the spectrum of primary con-

with slow colonic transit.16 The prevalence of methane-producing

stipation disorders, focusing on understanding pathophysiology,

flora—and baseline methane levels—is significantly higher in patients

diagnostic and clinical assessment tools, and pharmacologic and bio-

with delayed colonic transit than with normal transit, and negatively

feedback therapies.

correlate with colonic transit.17
The pathophysiology of CIC and IBS-C is multifactorial, involv-

2 | M E TH O DS

ing visceral hypersensitivity, neuropathy along the afferent gut-
brain axis, altered bile acid metabolism, neurohormonal regulation,
immune dysfunction, gut microbiota dysbiosis, alterations in the

For this review, during the period from February 2020 through

epithelial barrier, secretory properties and brain and gut dysfunc-

December 2020, literature searches were conducted using PubMed,

tion.18-20 These diagnoses of primary constipation are not exclusive,

CINAHL and Embase to identify publications reporting on the patho-

as patients may have co-existing defecation disorder, slow transit,

physiology, diagnostic criteria, diagnostic tools and approved treat-

CIC or IBS-C .3,11 Consequently, with an unrecognised or untreated

ments for constipation. Various combinations of search terms were

dyssynergia (or an overlapping rectal evacuation disorder), there is a

used for IBS-C , CIC or functional constipation and defecation disor-

potential for secondary delays in colonic transit.

der. Review of the reference lists from the above searches provided

Approximately, 40% of opioid-using patients report OIC regard-

additional references, as did additional targeted searches. In sum-

less of opioid potency. 21 Without treatment, opioid-related bowel

mary, 171 references were selected for inclusion in this review due

disorders, mainly constipation, significantly decrease the quality of

to their relevance to the scope of this manuscript and based on the

life (QoL) and daily activities. 22 The robust interaction of opioids

authors' insight, research experience and clinical practices in manag-

with µ-receptors in the enteric nervous system, rather than ef-

ing constipation.

fects of opioids in the central nervous system, results in decreased

|

1252

SHARMA et al.

GI transit, stimulation of non-propulsive activity, increased anal

constipation's varied features. 23,24 Visual images of stool form, spe-

tone, decreased intestinal secretion, increased fluid adsorption

cifically the Bristol Stool Form Scale (BSFS; Figure 1), and bowel

and decreased rectal sensitivity. The net effort of these mecha-

diaries are reliable methods to characterise bowel habits. A self-

nisms induced by opioids is to cause constipation and bowel-based

administered mobile phone app, Constipation Stool Diary, provides

dysfunctions.10

information about constipation symptoms that a patient can keep
prospectively for 1-2 weeks, reducing recall bias and improving
treatment response monitoring (Figure 2). 25

4 | D I AG N OS TI C TO O L S

Symptoms of chronic constipation alone do not accurately predict the underlying pathophysiology or response to treatment. 26

The term ‘constipation’ is non-specific, referring to a constellation

Providers should be familiar with ‘alarm features’ that suggest a more

of patient-reported symptoms describing a bowel function dis-

serious underlying health issue (eg, occult colon cancer), so appropri-

turbance. 23,24 However, clinicians should be able to characterise

ate testing (eg, colonoscopy) can be arranged. Alarm features include
bloody stools, anaemia or iron deficiency, unintentional weight loss
and family history of colorectal cancer.5,27

Separate hard lumps, like nuts

Type 1

4.1 | Diagnostic criteria
Sausage-shaped but lumpy

Type 2

Chronic constipation can be diagnosed via Rome IV criteria, which
incorporate patient-reported symptoms, stool consistency, physical

Like a sausage but with
cracks on the surface

Type 3

examination and motility study findings (Table 1). 28 In addition to
stool frequency, stool shape and consistency are also key components of the diagnostic criteria, and the BSFS is recommended for

Like a sausage or snake,
smooth and soft

Type 4

characterising stool appearance (Figure 1).3,28,29 The BSFS describes
seven stool consistency categories correlating with colonic transit
time. 29 Longer transit times are associated with lower BSFS scores.

Soft blobs with clear-cut
edges

Type 5

Sensations of incomplete emptying, straining, use of digital manoeuvres for evacuation of stool and abdominal bloating/distension can
indicate underlying constipation.4

Fluffy pieces with ragged
edges, a mushy stool

Type 6

Before diagnosing primary constipation, gastroenterology providers should first rule out secondary causes of constipation. A

Type 7

thorough medication history can identify exacerbating medications,

Watery, no solid pieces.

opioids and anti-cholinergic medications. Secondary constipation
may also be a result of diabetes mellitus, chronic renal disease, dehydration, Parkinson's disease, Ehlers-Danlos syndrome or other con-

F I G U R E 1 Bristol Stool Form Scale. Copyright 2000 © by Rome
Foundation. All Rights Reserved

Parameters in APP (n)

15

nective tissue disorders.3,30,31

Healthy subject
Constipation
***

10

Constipation
Stool Diary APP
***

5

***

0
CSBM

Time/BM

Gas episodes Bloating episodes
***P<0.001 vs healthy subject.

F I G U R E 2 Parameters in Constipation
Stool Diary in constipated and healthy
subjects. This figure has been reproduced
from Yan et al Gastroenterology 2020 with
permission from Elsevier. 25 BM, bowel
movement; CSBM, complete spontaneous
bowel movement
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Rome IV diagnostic criteria for IBS with constipation,43 functional constipation43 and functional defecation disorders28

IBS with Constipation (IBS-C)
Criteria fulfilled for the last 3 mo with symptom onset ≥6 mo prior to diagnosis
Recurrent abdominal pain, on average, ≥1 d per week in the last 3 mo, associated with two or more of the following criteria:
• Related to defecation
• Associated with a change in frequency of stool
• Associated with a change in form (appearance) of stoolDiagnostic criteria for IBS subtypes
Predominant bowel habits are based on stool form on days with at least one abnormal bowel movement a
IBS with predominant constipation: More than one fourth (25%) of bowel movements with BSFS types 1 or 2 and less than one fourth (25%) of
bowel movements with BSFS types 6 or 7
Alternative for epidemiology or clinical practice: Patient reports that abnormal bowel movements are usually constipation (like type 1 or 2 in the
picture of BSFS).
Functional constipation (Chronic idiopathic constipation [CIC])
Criteria fulfilled for the last 3 mo with symptom onset at least 6 mo prior to diagnosis
1. Must include two or more of the following:
• Straining during more than one fourth (25%) of defecations
• Lumpy or hard stools (BSFS 1-2) more than one fourth (25%) of defecations
• Sensation of incomplete evacuation more than one fourth (25%) of defecations
• Sensation of anorectal obstruction/blockage more than one fourth (25%) of defecations
• Manual manoeuvres to facilitate more than one fourth (25%) of defecations (eg, digital evacuation, support of the pelvic floor)
• Fewer than three spontaneous bowel movements per week
2. Loose stools are rarely present without the use of laxatives
3. Insufficient criteria for IBS-C
Functional defecation disorders
Criteria fulfilled for the last 3 mo with symptom onset at least 6 mo prior to diagnosis
1. The patient must satisfy diagnostic criteria for functional constipation and/or IBS-C
2. During repeated attempts to defecate, there must be features of impaired evacuation, as demonstrated by two of the following three tests:
• Abnormal balloon expulsion test
• Abnormal anorectal evacuation pattern with manometry or anal surface electromyography
• Impaired rectal evacuation by imaging
3. Subcategories F3a and F3b apply to patients who satisfy criteria for a functional defecation disorderF3a. Diagnostic criteria for inadequate
defecatory propulsion
Inadequate propulsive forces as measured with manometry with or without inappropriate contraction of the anal sphincter and/or pelvic floor
musclesb
F3b. Diagnostic criteria for dyssynergic defecation
Inappropriate contraction of the pelvic floor as measured with anal surface electromyography or manometry with adequate propulsive forces
during attempted defecationb
Abbreviations: BSFS, Bristol Stool Form Scale; CIC, chronic idiopathic constipation; IBS-C , IBS with constipation.
a

IBS subtypes related to bowel habit abnormalities can only be confidently established when the patient is evaluated off medications used to treat
bowel habit abnormalities.

b

These criteria are defined by age-and sex-appropriate normal values for the technique.

Primary chronic constipation can be further investigated by

or dyssynergic defecation.3,11,29,33,34 If constipation is fibre-and lax-

multiple tests. Defecatory disorders are evaluated by digital rectal

ative refractory, then physiological testing should be considered. 29

examination, rectal balloon expulsion, anorectal manometry and

Often, patients will have already attempted self-treatment with fibre

defecography.5,6,27

and laxatives before seeing a health care provider. 26

4.2 | Physical examination

4.3 | Functional tests

Comprehensive abdominal and thorough digital rectal examinations

High-resolution anorectal manometry and balloon expulsion

are useful in evaluating chronic constipation.11,32 Close inspection

testing are simple, inexpensive and the first anorectal physi-

of the perianal region can reveal excoriations, haemorrhoids, fis-

ological tests recommended for patients with laxative-refractory

sures or masses. A lubricated finger in the anal canal can assess anal

CIC or suspected dyssynergic defecation, with high sensitiv-

sphincter tone. Placing one hand on the lower abdomen while a fin-

ity for detecting dyssynergia and rectal hypersensitivity or

ger is inserted into the anal canal assesses rectoanal incoordination

hyposensitivity.4,11,28,32

1254
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4.3.1 | Balloon expulsion test

(barium) or magnetic resonance imaging. 28,32,35 X-ray defecography
assesses rectal wall structure and pelvic floor motion while seated.

The balloon expulsion test is an office-based test assessing a pa-

Magnetic resonance imaging defecography evaluates all pelvic com-

tient's ability, based on time taken, to expel a water- or air-filled

partments in the semi-recumbent position, which may not replicate

balloon inserted into the rectum. 28,32,35,36 Standardisation is lacking

the everyday practice of defecation.35 These tests can determine

and methodology differs between GI motility laboratories,

32,35

but

if chronic constipation is associated with incomplete anal opening,

an expulsion time longer than 1-2 minutes is generally considered

impaired puborectalis relaxation or contraction, abnormal perineal

abnormal. 28 An uncontrolled study of patients with constipation and

descent and anatomical abnormalities (eg, rectocele, prolapse or

defecation disorders illustrated that the balloon expulsion test may

intussusception).5,29

identify patients with dyssynergic defecation.

37

Some GI motility

laboratories use the balloon expulsion test to screen for dyssynergic
defecation. However, a normal test does not always exclude defeca-

4.4 | Assessing colonic transit time

tory dysfunction, and correlation with other anorectal physiological
testing and defecography is lacking.5,11,29,38 Patient demographics

Slow colonic transit time can contribute to constipation and is as-

can also affect test results: males typically have a shorter expulsion

sessed by measuring the time taken for content to move through

time, and expulsion time lengthens with increasing age.35 Therefore,

the GI system. 32 Colonic transit assessment is recommended in

corresponding tests of anorectal physiological function should be

the evaluation of laxative-refractory constipation.11,32 Specialist

obtained.

28,29

centres evaluate colonic transit time either by radiopaque markers, wireless motility capsules or by scintigraphy. 5,11,27,28,42 Colonic
transit tests should be performed while the patient is not taking a

4.3.2 | Anorectal manometry

laxative.43

Anorectal manometry assesses anorectal pressure changes during
rest and simulated defecation of an intrarectal balloon, sphincter

4.4.1 | Radiopaque marker test

tone and rectoanal reflexes (which evaluate intrinsic and extrinsic
innervation, and rectal compliance and sensitivity).5,28,29,32 Although

Radiopaque marker testing is widely accessible, non-invasive, inex-

more expensive, high-resolution anorectal manometry using a six-

pensive and the most common option for assessing colonic transit

sensor, solid-state probe permits easier calibration and shorter pro-

time.5,28,29,42 In a radiopaque marker test, the patient ingests a dis-

cedure time compared to conventional water-perfused anorectal

solvable capsule containing 20-50 plastic markers.42 The radiopaque

manometry.

39

Anorectal manometry is useful in diagnosing dyssyn-

markers are visible on X-ray. Transit time is calculated from abdomi-

ergic or disordered defecation and other neuromuscular and sensory

nal radiographic images captured at set time points in the days fol-

problems, and identifying patients who may benefit from biofeed-

lowing capsule ingestion.42 Variations in the radiopaque marker test

back therapy.5,32,40,41

are used in gastroenterology clinical practice.42 The most commonly

While effective and widely used, anorectal manometry has lim-

applied method involves administering a capsule containing 20-24

itations. Substantial variations in clinical practice in methodologies

markers on day 1, followed by abdominal radiograph imaging after

used for the balloon expulsion test and anorectal manometry32,36

5 days29,42; retention of >20% of ingested markers indicates slow

demand prompt efforts to standardise testing protocols.36,40 A

colonic transit. 29

standardised protocol of high-resolution anorectal manometry
can characterise dyssynergic defecation subtype of rectoanal incoordination and guide therapists providing corrective biofeedback

4.4.2 | Wireless motility capsule test

therapy treatment. 36 Furthermore, patient cooperation is key,11
the procedure may be embarrassing11 and test performance may

Wireless motility capsules enable radiation-f ree, continuous mon-

not accurately replicate the actual act of defecation. 28 If the bal-

itoring of the intraluminal pH, pressure and temperature while

loon expulsion or anorectal manometry test fails to diagnose or

passing through the GI tract. 29,42,44 Signals from the capsule are

exclude a strongly suspected defecatory disorder, defecography is

transmitted to a receiver the patient wears. After capsule inges-

11,28

recommended.

tion following an overnight fast, patients record events (eg, meals,
bowel movements, symptoms) over 3-5 days by pressing a receiver button and maintain a diary.44 Results have demonstrated

4.3.3 | Defecography

good correlation with radiographic tests. 28,44,45 Wireless motility
capsules provide a comprehensive picture with other regional GI

Defecography examines both the function and structure of the

transit times (gastric emptying time, small-b owel transit time) and

anorectum and the pelvic floor during voluntary defecation. 28,29

whole-g ut transit time.44,46 The capsule measures colonic transit

Defecography is performed in specialist centres, using X-ray

time by detecting pH changes while moving through the gut. 29,44

|
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Demographics and study protocols can influence test findings.47

of a patient's stools via BSFS would reveal more than 25% of bowel

Transit times are shorter among males and can vary with the men-

movements with BSFS types 1 or 2 and less than 25% of bowel

strual cycle.47

movements with BSFS types 6 or 7.43 Predominant abdominal pain
would likely distinguish IBS-C from CIC. Laxatives may help improve
bowel movement frequency, but they may not improve abdominal

4.4.3 | Scintigraphy

symptoms (eg, bloating and pain). Digital rectal examination, anorectal manometry and balloon expulsion would determine the coexist-

Scintigraphy uses repeated imaging of ingested radioisotopes over

ence of disordered or dyssynergic defecation.

consecutive days to calculate overall and regional colonic transit
times. 29,42 A range of γ-emitting isotopes, administered in varying

vehicles, may be used.42 Scintigraphy testing is conducted at a few

5.3 | Defecatory disorder

specialised centres, due to the need for specialist equipment and use
of short-lived radioactive isotopes.42

As with CIC, patients may have infrequent and hard bowel movements, bowel movements associated with excessive straining, or a
feeling of incomplete evacuation, and may use digital evacuation ma-

4.4.4 | Colonic manometry

noeuvres. Laxatives may not improve feelings of incomplete evacuation, straining and hard stools. A detailed history may reveal natural

In cases of severe slow-transit constipation and suspected colonic

birth experience in women. Digital rectal examination, rectal balloon

inertia, ambulatory 24-hour colonic manometry following a stand-

expulsion, anorectal manometry and defecography would help diag-

ardised protocol can help distinguish between underlying colonic

nose defecatory disorders. 27 In a digital rectal examination, a patient

myopathy and neuropathy, facilitating appropriate management.48

may have a normal sphincter tone at rest, but when asked to push

Like scintigraphy, colonic manometry is limited to a few, specialised

and bear down may exhibit paradoxical contraction of anal sphincter

centres.

with no perineal descent, suggesting dyssynergia.34 The patient may
be unable to pass the balloon expulsion test,37 and results from ano-

5 | D I AG N OS TI C FE AT U R E S
5.1 | Chronic idiopathic constipation
CIC is estimated to affect 14% of the global population.1 Patients

rectal manometry would show consistency with dyssynergic defecation. Biofeedback therapy using visual manometry-based feedback
would likely be helpful.

6 | TR E ATM E NT

with CIC may report lumpy or hard stools (BSFS type 1-2) and infrequent bowel movements (<3 per week). Straining and abdominal

The initial management approach to IBS-C and CIC tends to be simi-

bloating may be present. Pain may also be present, but it would not

lar, but therapy response varies between the two conditions.9 For

predominant.

43

Evaluation of patient's history may find sensation of

example, stimulant laxatives and polyethylene glycol (PEG) can be

incomplete evacuation or anorectal obstruction, and patients may

effective for CIC but not for IBS-C .9 The symptomatology of def-

report using manual manoeuvres to facilitate defecations. Discussion

ecatory disorders, such as dyssynergic defecation, can overlap with

with the patient may reveal limited physical activity, QoL complaints,

IBS-C and CIC; however, symptoms of excessive straining, feeling of

attempted use of laxatives and infrequent loose stools without the

incomplete evacuation and use of digital manoeuvres to defecate

use of laxatives. A rectal examination and routine blood tests would

are more prevalent. Defecatory disorders are less likely to respond

likely be normal and there may be no immediate indication of alarm

to laxative therapy and more likely to require biofeedback therapy. 2

features or physical abnormalities. More invasive diagnostic tests
may be necessary if symptoms are not relieved with prescription
therapy. In patients with laxative-refractory constipation, colonic

6.1 | Lifestyle and dietary modifications

transit assessment may be informative.
Initial therapy for chronic constipation includes lifestyle and di-

5.2 | IBS with constipation

etary modifications (eg, increasing fluid and fibre intake) and physical activity. 28,29,32 Little evidence suggests that increasing fluid
intake alone improves stool consistency among adequately hy-

Approximately 5.2% of the North American population is estimated
to experience IBS-C .

49

In order to diagnose IBS-C based on the Rome

IV criteria, a review of the patient's medical history would reveal re-

drated patients. 28,29,50 Instead, increased fluid intake is most beneficial when combined with additional fibre in patients with mild
constipation. 28,32,50

current abdominal pain associated with defecation, reductions in

Increasing fibre intake, which should be done gradually to pre-

stool frequency and/or a change in stool consistency.43 Assessment

vent abdominal distension,11,28,32 may improve constipation by

|
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stimulating the gut mucosa to secrete water and mucus and im-

electrolyte secretion and peristalsis upon activation by glycosidases

29

in the colon. 28,29,32,50 Stimulant laxatives are commonly used for pa-

prove stool consistency by increasing its water-holding capacity.

However, not all constipation patients benefit from additional di-

tients with CIC and IBS-C , though large controlled studies are lack-

etary fibre.50 Insoluble fibre (eg, fibre in wheat bran and whole grains)

ing. 29,50 Both bisacodyl and sodium picosulfate can improve stool

may worsen symptoms of abdominal pain, distension and flatulence

consistency and frequency, straining and QoL compared with pla-

Fruit fibre (eg, prunes ) or mixed soluble

cebo in CIC patients in randomised controlled trials.62-6 4 The most

has demonstrated a short-term efficacy in the management

common AEs with stimulant laxatives include diarrhoea, abdominal

in some patients.
fibre

52

28,29,32

51

of chronic constipation, somewhat better than psyllium. In a recent

pain, nausea, vomiting and headache. 28,32,62

randomised controlled trial of natural treatments for CIC in 79 patients, kiwifruit, psyllium and prunes were found to be effective.53
Physical activity has been associated with reduced GI transit

6.2.2 | Prokinetic and prosecretory agents

times.50 Although exercise alone does not appear to improve constipation, patients report improved QoL and a reduction in symptom
severity.

50

Table 2 and Figure 3 detail the mechanisms of action by which the
following types of prokinetic and prosecretory agents improve constipation symptoms.

6.2 | Pharmacological therapy

Guanylate cyclase-C receptor agonists
Guanylate cyclase-C (GC-C) receptors are transmembrane proteins

6.2.1 | Laxatives

expressed by intestinal epithelial cells and help maintain bowel
function by regulating fluid and electrolyte balance in the gut.65

Laxatives are an inexpensive, widely available and often over-the-

Activated GC-C receptors facilitate the production of an ion gra-

counter (OTC) treatment option for chronic constipation refractory

dient between the intestinal membrane and intestinal lumen that

to lifestyle and dietary modifications.11,32 Laxatives can improve

promotes net water movement into the gut 27,66 by simultaneous

stool consistency, increase stool frequency and reduce defecation

activation of cystic fibrosis transmembrane conductance regulator

straining.54

channels and inhibition of sodium/hydrogen exchanger isoform 3
channels.65,67 Furthermore, GC-C receptor activation helps maintain

Osmotic laxatives

the intestinal mucosal barrier, prevent inflammation and attenuate

Osmotic laxatives, such as PEG, lactulose, sorbitol, glycerol and

visceral pain sensations.67

magnesium salts, contain non-absorbable ions or molecules. 28,32

The GC-C receptor is activated by the hormones uroguanylin

These compounds create an osmotic gradient that promotes water

and guanylin and by heat-s table enterotoxins produced by diar-

and electrolyte secretion into the intestinal lumen, increasing faecal

rhoeagenic bacteria. 67 Uroguanylin and guanylin both have two

volume and improving peristalsis. 29,32 Most studies have focused on

disulphide bonds resulting in a flexible structure with active forms

PEG, which has demonstrated superiority over placebo and lactulose

stabilised at a specific pH. 67 Uroguanylin binds more readily to

in improving symptoms of chronic constipation.

29,50

PEG treatment

GC-C receptors in slightly acidic conditions of the duodenum and

shows greater resolution of constipation symptoms,55,56 improved

jejunum (pH 5-6), while guanylin binds to GC-C receptors in more

stool consistency and frequency,55-57 shorter GI transit time,57 less

neutral to slightly basic conditions of the ileum and the colon (pH

straining,55-57 and less severe abdominal bloating and pain compared

7-8). 65,67 In contrast to uroguanylin and guanylin, heat-s table en-

55

PEG is also better than lactulose in improving stool

terotoxins produced by diarrhoeagenic bacteria are stabilised by

consistency and frequency, reducing abdominal pain, and need for

a third disulphide bond, producing a more stable and higher affin-

additional constipation-related treatment.58,59 Improvements in

ity structure. 67 Heat-s table enterotoxins lack pH-s ensitive amino

bowel movements, stool consistency and straining with PEG treat-

acids, allowing for GC-C binding throughout the GI tract without

ment have also been observed in patients with IBS-C , though ab-

being affected by gut pH. 67

with placebo.

dominal pain is largely unaffected.

50,60,61

Osmotic laxatives are

GC-C also helps regulate pain experienced in patients with

generally well tolerated.32,55,60 The most common adverse events

chronic constipation, especially those with IBS-C . 26,68 Activation

(AEs) are abdominal pain and distension, diarrhoea, nausea, flatu-

of GC-C inhibits nociception in the gut, reducing pain.68 GC-C is a

lence and vomiting.

28,56,57,61

Magnesium compounds should be used

with caution in patients with renal impairment.

target for pharmacological therapy because activating this receptor
can increase fluid secretion and accelerate colonic transit time, restoring normal bowel function.65,68 Furthermore, a recent report has

Stimulant laxatives

demonstrated reduced uroguanylin levels in IBS-C and CIC patients

Stimulant laxatives are recommended after patients have failed to

when compared to healthy control subjects during fasting and after

respond to osmotic laxatives.11,29 Diphenylmethane derivatives (eg,

meals.69

bisacodyl, sodium picosulfate) and anthraquinones (ie, sennosides,

Linaclotide, a synthetic analogue of exogenous diarrhoeagenic

cascara) are inactive, non-absorbable glycosides that stimulate fluid,

bacterial heat-stable enterotoxins, and plecanatide, a synthetic
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Mechanism of action of pharmacological treatments for chronic constipation

Drug

Recommended
dosea

Polyethylene
glycol

Non-prescription Osmotic
laxative

Bisacodyl

Non-prescription Stimulant
Non-prescription laxative

Sodium
picosulfate

Mechanism of action

Efficacy

Adverse events

• Creates an osmotic
gradient that promotes
water and electrolyte
secretion into the
intestinal lumen

• Improves stool consistency and
frequency55,57
• Reduces straining55,57

• Abdominal pain and
distension, diarrhoea,
nausea, flatulence,
vomiting28,29,56,61

• Stimulates water and
electrolyte secretion,
and peristalsis

• Improves stool consistency
and frequency, straining and
QoL62-6 4

• Diarrhoea, abdominal
pain, nausea, vomiting,
headache28,32,62

Anthraquinones Non-prescription
GC-C agonist • Increases intracellular
• Improves stool consistency and
cyclic guanosine
frequency, reduces straining
monophosphate, creating
and abdominal discomfort,
an ion gradient that
improves QoL 54,70-82
promotes fluid secretion • Reduces abdominal
pain, bloating and
• Inhibits colon
cramping71-73,78,80-83
nociception

• Diarrhoea54,70-82,84,85

5-HT4
agonist

• Accelerates GI motility

• Nausea, abdominal
pain, diarrhoea,
headache54,96-98,101,102
• Cardiovascular events93

IBS-C: 50 mg
b.i.d.

Sodium/
hydrogen
exchanger
isoform 3
inhibitor

• Creates an ion gradient
• Improves constipation
that promotes water and
symptoms, including stool
sodium secretion into the
consistency and frequency, and
intestinal lumen
abdominal pain103

• Diarrhoea103

CIC: 24 mcg
b.i.d.
IBS-C: 8 mcg
b.i.d.d

Type-2
chloride
channel
activator

• Creates an ion gradient
• Improves stool consistency and
that promotes water and
frequency, reduces straining,
sodium secretion into the
bloating and pain54,113-122
intestinal lumen

• Nausea,
diarrhoea54,113-118,121,122

Plecanatide

CIC or IBS-C:
3 mg q.d.

Linaclotide

CIC: 145 mcg
q.d. and 72
mcg q.d.
IBS-C: 290 mcg
q.d.

Prucalopride

CIC: 2 mg q.d.b

Tegaserod

IBS-C: 6 mg
b.i.d.c

Tenapanor

Lubiprostone

• Improves constipation
symptoms, including stool
consistency and frequency,
straining QoL96-98,167

Abbreviations: b.i.d., twice daily; CIC, chronic idiopathic constipation GC-C , guanylate cyclase-C; GI, gastrointestinal; IBS-C , IBS with constipation;
q.d., once daily; QoL, quality of life.
a

Prescription doses are based on US Food and Drug Administration approval. Not all prescription therapies are approved outside the United States;
treatment options should take into account therapy availability.

b
c

Indicated for patients with CIC (2 mg q.d.) or for patients with severe renal impairment (1 mg q.d.)

Indicated for women aged <65 y.

d

Indicated for women aged ≥18 y.

uroguanylin analogue, are GC-C agonists approved by the US Food
and Drug Administration for the treatment of CIC and IBS-C .

66

and occurs during the first 4 weeks of treatment. 54,70-82,84,85 No

In

head-to-head trials have been conducted, and so direct com-

clinical studies, linaclotide and plecanatide significantly improved

parisons cannot be made between the products; however, rates

stool consistency and frequency, and reduced straining, in patients

of diarrhoea reported in clinical trials of linaclotide were higher

Patients also report improvements in ab-

relative to those in plecanatide trials.71,73,76-79 While this may be

54,70,73-79,82,83

related to the similarity of plecanatide to endogenous uroguanylin

with sustained efficacy over 24 and 52 weeks of treatment.82

and linaclotide to heat-s table enterotoxins, 67 there were also dif-

Linaclotide and plecanatide also reduce abdominal pain, bloating

ferences between the plecanatide and linaclotide study designs

with CIC or IBS-C .

54,70-81

dominal discomfort, constipation severity and QoL,

71,72,78,80-83

and cramping in patients with IBS-C .

Improvements in

that should be considered. Linaclotide, but not plecanatide, trials

IBS-C symptoms were maintained over 12 and 26 weeks of treat-

permitted dose interruptions (ie, patients could halt treatment to

ment.83 Japanese patients with IBS-C may require a higher dose

resolve a diarrhoea AE), which may have contributed to artificially

of linaclotide, possibly due to differences in GC-C polymorphisms,

lower rates of discontinuation due to diarrhoea. Additionally, while

bacterial proteases that metabolise linaclotide and/or diet compared

in both trials any verbatim report of ‘diarrhoea’ was recorded as an

with Western patients.82

AE, in plecanatide studies, an extra level of scrutiny was added.

Linaclotide and plecanatide are well tolerated. Diarrhoea is the

When a patient reported increased stool frequency or looser

most frequent AE, but is generally mild or moderate in severity

stools, an assessment of ‘bothersome’ was made to determine if
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Drug

Serotonin

Mechanism
or drug
target

Ghrelin
receptor

Bile acids

5-HT4

Tenapanor

Lubiprostone

Cl-

Cl-

Elobixibat
Enteroendocrine cell.

Lumen

Linaclotide
Plecanatide
CFTR

IBAT

Ileum

Nutrients and/or food

NHE3

ClC-2
channel

GC-C
receptor

Tight
junction

Intestinal
epithelial
cell

GTP

Mucosa

cGMP

ACh
and VIP

Submucous
plexus

Prucalopride

Smooth muscle cell

Pain Fiber

F I G U R E 3 Mechanism of action of agents used for the treatment of constipation. This figure has been modified from Simrén et al Nature
Reviews Gastroenterology & Hepatology 2018 with permission from Springer Nature Customer Service GmBH: Wiley.171 ACh, acetylcholine;
CFTR, cystic fibrosis transmembrane conductance regulator; ClC-2, type-2 chloride channel; GC-C , guanylate cyclase-C; IBAT, ileal bile acid
transporter; NHE3, sodium/hydrogen exchanger 3; VIP, vasoactive intestinal polypeptide

this report should be recorded as diarrhoea AE or a desired effect

agonists, including cisapride and tegaserod, had poor selectiv-

of the drug. 86

ity and low affinity for the 5-H T4 receptor, were associated with
serious cardiovascular AEs, and, consequently, market with-

Serotonin agonists

drawal.92,93 After data re-e xamination, tegaserod has been re-

Serotonin (5-hydroxytryptamine) is a gut neurotransmitter that

approved for the treatment of IBS-C in women <65 years old,

promotes motility via several serotonin receptor subtypes in the GI

with a contraindication in patients with a history of cardiovascu-

tract.

28,87

Serotonin controls gut smooth-muscle contractions and

relaxations.

88

lar issues.95 In randomised, placebo-controlled phase 3 studies,

Patients with IBS-C may have dysfunctional serotonin

prucalopride was superior to placebo in improving symptoms,

neurotransmission in the gut.87,88 In a healthy individual, serotonin

stool consistency and frequency, and reduced straining on defe-

plasma levels increase after food consumption; however, in IBS-C

cation in patients with CIC.96-98 Improvements in disease sever-

Alternatives in

ity and QoL,96-98 with patient satisfaction of bowel pattern, were

serotonin transporter gene polymorphism in IBS and in constipation

noted and treatment efficacy was maintained for ≥18 months.99

patients, there may be limited or no response.
90

have been reported.

88,89

This dysfunctional serotonin signalling may

Prucalopride's efficacy for improving symptoms of constipation

be associated with altered colonic transit.89 In patients with slow-

was confirmed in several integrated analyses and meta-a nalyses;

transit constipation, levels of serotonin-immunoreactive cells are

however, no evidence has been published demonstrating efficacy

significantly lower, so cell secretory indexes are decreased in these

for pain so prucalopride is not approved for the treatment of

patients' colons.91

IBS-C . 54,100-102

Several agents have been developed that target the serotonin receptor 5-H T4 to promote peristalsis and secretion.

92,93

Prucalopride-a ssociated AEs include GI complaints (nausea, abdominal pain, diarrhoea), flatulence and headache. 54,96-

Prucalopride and velusetrag (currently under clinical investi-

98,100-102

gation) are selective, high-affinity 5-H T4 agonists that increase

generally being mild, transient and resolving after the first day of

GI motility and reduce colonic transit times.92-94 Earlier 5-H T4

However, prucalopride is well tolerated, with AEs

treatment.96,99,102
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Sodium/hydrogen exchanger isoform 3 inhibitors

stool consistency and frequency and in reducing straining, bloating

Inhibition of GI sodium/hydrogen exchanger isoform 3 expressed on

and constipation severity in patients with CIC or IBS-C .7,54,113-121

the apical surface of the small intestine and colon reduces absorp-

Lubiprostone treatment also reduces abdominal pain/discomfort and

tion of sodium from the small intestines and colon.103 This results in

improves QoL for patients with IBS-C .115,117,118,120,121 Improvements

water secretion into the intestinal lumen, increases intestinal transit

are maintained with long-term treatment.113,117,120

time and softens stool consistency. Tenapanor, a sodium/hydrogen

GI-related AEs are most common with lubiprostone treatment

exchanger isoform 3 inhibitor, is approved by the US Food and Drug

(predominantly nausea and diarrhoea), though headaches were also

Administration for IBS-C treatment.103

reported.54,113-118,121,122 AEs tend to be mild or moderate in intensity

In a phase 3 study, patients treated with tenapanor demon-

and short lived.113-115,117,118,121 A recent study using pooled trial data

strated improvements in stool frequency and reductions in abdomi-

demonstrated that lubiprostone did not affect electrolyte homeo-

nal pain.103 Diarrhoea was the most common adverse reaction, with

stasis in the short or long term.123

treatment-related diarrhoea reported in 13.3% of tenapanor-treated
patients.103

Opioid receptor antagonists
The mechanism by which opioid medications induce constipation is

Bile acid modulation

complex, involving peripheral and central effects. Peripheral activa-

Dysfunction in the enterohepatic circulation of bile acids can cause

tion of µ-opioid receptors in the stomach and intestines inhibits both

constipation.87 Bile acids that are not absorbed in the terminal ileum

excitatory and inhibitory neural pathways, diminishing peristalsis

can stimulate water and electrolyte secretion in the colon and di-

and colonic transit time and delaying gastric emptying.124 Evidence

rectly contribute to colonic motility independent of secretory ef-

for a central mechanism is supported by a study in rats where intra-

fects.104 A subset of patients with IBS-C may exhibit lower bile

cerebroventricular morphine administration inhibited GI propul-

acid levels in their stools than in those of healthy controls and of

sion.124 In patients with laxative-refractory OIC, opioid receptor

patients with diarrhoea-predominant IBS,

87

which may be attributed

antagonists with peripheral or peripheral and central action may be

to altered bile acid synthesis in these patients.105 Modulation of the

used. Although OIC is a secondary cause of constipation, many of

bile acid cycle may help treat chronic constipation and involves bile

which may be relieved by treating the primary problem, it is the only

acid supplementation or inhibition of the ileal bile acid transporter.

secondary cause of constipation with specific therapies and is po-

Sodium chenodeoxycholate is a bile salt that can accelerate colonic

tentially reversible with treatment (unlike other secondary causes).

transit times and improve stool consistency and frequency in pa-

Several therapies for OIC are approved by the US Food and Drug

tients with chronic constipation, including IBS-C .106,107

Administration.125 The American Gastroenterological Association's

Elobixibat (approved in Japan) is a minimally absorbed, highly

guidelines on the management of OIC distinguishes between tradi-

selective ileal bile acid transporter inhibitor. By inhibiting the ac-

tional laxatives and peripherally acting µ-opioid receptor antagonists

tive reabsorption of bile acids in the ileum, elobixibat increases

and other prescription therapies for this condition. These guidelines

bile acid concentrations in the colon, promoting fluid secretion

recommend traditional laxatives (including PEG) as first-line treat-

and motility.108 Elobixibat increases stool frequency and improves

ment for OIC, while peripherally acting µ-opioid receptor antago-

constipation-associated symptoms, including stool consistency, con-

nists and other prescription therapies are recommended for patients

stipation severity, straining and abdominal bloating in CIC and IBS-C

who fail traditional laxatives.126 Meta-analysis of the safety and ef-

108-110

ficacy of current OIC treatments has recently been published.127

patients.

Both sodium chenodeoxycholate and elobixibat are generally
well tolerated. AEs are typically mild and GI-related, most commonly
abdominal pain and diarrhoea.107-110 Given elobixibat demonstrates
minimal systemic absorption,110 increased bile acids may stimulate

6.3 | Biofeedback therapy for
dyssynergic defecation

propagated contractions in the colon, resulting in abdominal pain
and cramping.111

Biofeedback therapy is a robust treatment for dyssynergic defecation diagnosed by symptoms and anorectal motility testing, receiv-

Chloride channel activators

ing a Grade A recommendation by the American and European

Chloride channels located on intestinal epithelial cells regulate in92

testinal motility and fluid secretion.

Societies of Neurogastroenterology and Motility.128 Multiple ran-

Activation of type-2 chloride

domised controlled studies have proven that four to six sessions of

channels triggers the release of chloride ions into the intestinal

electromyography or manometry-based biofeedback therapy carries

lumen.92 The resulting ion gradient promotes sodium and water re-

a 70%-8 0% efficacy rate for dyssynergic defecation compared to

lease into the lumen, increasing stool volume and GI motility while

standard treatment,129 diltiazem130 or laxatives.131 Furthermore, bi-

92

reducing colonic transit time.

ofeedback therapy, incorporating rectoanal coordination, simulated

Lubiprostone, a bicyclic fatty acid and a prostaglandin E1 an-

defecation and sensory conditioning, is durable, and separate stud-

alogue, is a locally acting selective type-2 chloride channel ago-

ies have shown a sustained response for 12 and 44 months.132,133

nist. 28,32,92,112 Lubiprostone has demonstrated efficacy in improving

Severe constipation, digital facilitation of defecation, delayed
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colonic transit, impaired rectal sensation and increased anorectal

constipation treatments has been published.139 First-line treatment

angle during squeeze are predictors of poor response to biofeed-

for chronic constipation patients failing lifestyle modifications in-

back therapy.134-136 Standard office-based biofeedback therapy suf-

clude fibre supplements or osmotic laxatives (such as PEG) on a reg-

fers from limitations: the need for skilled staff, multiple visits and

ular basis, or stimulant laxatives intermittently,50 which are available

limited availability at expert centres. Home biofeedback therapy is

to patients as OTC products.11,28,29,32,140 Indeed, many patients with

appealing for dyssynergic defecation and has similar efficacy in im-

chronic constipation will use some OTC laxative before consulting a

provement of bowel symptoms and balloon expulsion compared to

health care provider.141 Patients try an average of three OTC prod-

137

office-based therapy.

ucts before seeking help141; however, only half feel satisfied.7,141

Furthermore, home biofeedback therapy is

more cost-effective and shows promise for the future.138

Primary care providers should refer patients who are laxative
refractory or intolerant to treatment to a gastroenterology provider for further assessment. 28,140 Primary care providers may try

6.4 | Clinical approach to managing patients with
constipation

a promotility agent or prosecretory agent while awaiting gastroenterology evaluation. Gastroenterology providers may further titrate
promotility agents or prosecretory agents and/or consider further

Management algorithms are available to help guide treatment deci-

testing—such as anorectal manometry, barium or magnetic reso-

sions (Figure 4) and a recent meta-analysis evaluating the efficacy of

nance defecography, or colon transit time assessment—to identify

Primary Chronic
Constipation

Dietary and Lifestyle Modifications
• Adequate Fiber Intake + Fiber Supplement
• Regular Exercise
• Stool Softeners, Bulk Laxatives, Prunes, Kiwifruit
Unresponsive

Rescue
Therapy
Stimulant
Laxatives
• Senna
• Bisacodyl

•
•
•

Osmotic Laxatives
PEG Compounds
Lactulose
Mg-Containing Laxatives

No bowel
movement
in 3 days

Unresponsive

Laxative-Refractory
Chronic Idiopathic Constipation

Naloxegol
Lubiprostone
Methylnaltrexone
Naldemedine

Opioid-Induced Constipation

Suspect Dyssynergia

Linaclotide
Lubiprostone
Plecanatide
Prucalopride
1. Wireless Motility Capsule (Gastric Emptying Scintigraphy
and Colonic Transit Test, if WMC Unavailable)

Unresponsive

Dyssynergia Absent

2. Colonic Manometry for Delayed Colonic Transit

Present

Biofeedback
Therapy

Present

Absent
Intensive Medical/
Behavioural Therapy

High-Resolution Anorectal
Manometry
Balloon Expulsion Test

Colonic Neuropathy?

Colectomy

F I G U R E 4 Management algorithm for the treatment of constipation. This figure has been modified from Sharma Handb Exp Pharmacol.
2017 with permission by Springer Nature Customer Service GmBH: Wiley.4 Mg, magnesium; PEG, polyethylene glycol; WMC, wireless
motility capsule
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the underlying pathophysiology and guide treatment in treatment-
11,28,50

refractory patients.

While there is a lack of evidence in the

1261

trials and associated morbidity, antegrade continence enema cannot
be recommended for treatment of severe constipation.

literature to guide a symptom-based therapeutics approach, there
is some evidence that different therapies may improve certain underlying mechanisms. For example, biofeedback therapy—a be-

6.5 | Patient perspective

havioural training technique using visual feedback to correct pelvic
floor contractions—is safe, effective and recommended for patients

6.5.1 | Tools for assessing symptom severity

with defecation disorders on the basis of anorectal manometry and
defecography findings,11,29,32,50,140 linaclotide and prucalopride ac-

Patient QoL decreases with severity and duration of constipation

celerate colonic transit time, and linaclotide and plecanatide improve

and associated symptoms.7 Furthermore, patients with chronic

abdominal pain (and the former has been shown recently to modify

constipation exhibit significant psychological stress and impaired

afferent gut and brain interactions).19 Likewise, rectal sensory re-

health-related QoL compared to control subjects.163 Symptoms re-

training may be helpful in addition to biofeedback therapy to address

ported as most bothersome are often also the most severely per-

both rectal hyper-and hyposensitivity.

ceived.7 Therefore, treatments focused on these symptoms are

A gastroenterology provider may recommend alternative treatments if other treatment options have failed.

50

Acetylcholinesterase

inhibitors, such as neostigmine, can dramatically increase GI mo-

important to improve QoL.7 Improvement in constipation with both
secretagogues73,75-77,79 and biofeedback therapy138 can improve
QoL.

tility and may be considered in hospitalised patients with colonic

In the absence of objective biomarkers for assessing con-

pseudo-obstruction; however, its use requires close observation

stipation severity, prospective stool diaries and validated se-

and cardiorespiratory monitoring in the intensive care setting.50,142

verity scales help assess patient-reported outcomes in clinical

Furthermore, pyridostigmine, an oral acetylcholinesterase inhibi-

trials and manage patients clinically.164 The most commonly used

tor, may be considered in severe constipation, especially with co-

scales include the Constipation Assessment Scale, Constipation

existing autonomic dysfunction in patients who have previously

Scoring System, Symptom Severity Score and Patient Assessment

responded to neostigmine or diabetes.143,144 Oral ingestion of

Constipation-Symptom (Table 3). These scales assess the presence

a vibrating capsule alters colonic circadian rhythm and may im-

of constipation, constipation severity and the most bothersome

prove constipation by inducing more complete spontaneous bowel

constipation-associated symptoms. Thorough review of stool dia-

movements.145 Habit training (bowel or pelvic floor retraining) and

ries and responses to severity scales may offer clinicians an oppor-

psychological interventions (cognitive behavioural therapy, hypno-

tunity to assess treatment efficacy from the patient's perspective.

therapy, psychological therapy) are also recommended for patients

However, if physical stool diaries and scales are not completed in

failing to respond to standard care.

50,146

Total abdominal colec-

tomy is reserved for rare, severe cases of colonic inertia after all

real time, they may be limited by their dependence on patient recall
of bowel habits and symptoms.

non-surgical options have failed and specialised testing such as co-

New tools are becoming available to support the monitoring of

lonic manometry suggests underlying colonic neuropathy.11,32,50,147

patients with constipation, such as electronic health records, smart-

Continuous direct nerve stimulation (sacral nerve stimulation) is the

phone apps and electronic stool diaries. The National Institutes

least-invasive surgical option available, with fewer complications

of Health Patient-Reported Outcomes Measurement Information

than other surgeries; however, data demonstrating efficacy are lack-

System is increasingly incorporated into electronic health records

ing.50,147 Subcutaneous electrodes can stimulate the sacral nerve to

as a measure of recording patient-reported outcomes.164 Within the

32,147

GI domains of the National Institutes of Health Patient Reported

Antegrade continence enema, an endosurgical procedure where ap-

Outcomes Measurement Information System, abdominal pain and

pendicocecostomy or caecostomy is created to serve as a conduit

constipation, as well as diarrhoea as a potentially treatment-related

to directly administer enemas into the caecum, has been described

adverse event, are relevant to patients with constipation.164

induce propagating contractions and increase stool frequency.

as an efficacious option to treat faecal incontinence and refractory

With smartphone apps and diaries, gastroenterology provid-

constipation.148 The majority of cases and much of the literature are

ers can potentially review patients' symptoms as recorded in real

focused on the treatment of children; however, single-centre expe-

time. The GI Patient Reported Outcomes Measurement Information

riences have described their long-term outcomes in adults.149-161 A

System scales can be accessed via the MyGiHealth app online and on

meta-analysis of observational studies, only three of which were

smartphones, which compare a patient's symptoms scores with those

prospective, suggested that approximately two thirds of antegrade

of the general population in the United States and generates a heat

continence enema procedures for constipation were efficacious,

map of symptoms.164 This app can also track changes across time, al-

defined by continued use on follow-up or successful resolution of

lowing gastroenterology providers to assess treatment efficacy and

symptoms, and approximately 45% of antegrade continence enema

facilitate improved outcomes for both providers and patients.164 The

procedures were associated with morbidity, most commonly wound

Constipation Stool Diary is an app-based questionnaire used to track

infection and stomal stenosis, with a re-operation rate of >25%.162

patient symptoms and medication use. 25 Apps have demonstrated a

Given the low quality of evidence without randomised controlled

level of accuracy comparable to a physical diary and may be patient
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Commonly used scales for assessing the severity of constipation

Scale

Description

Scoring system

Scoring interpretation

Constipation Assessment
Scale168

Evaluates eight items:
• Abdominal distension or bloating
• Change in gas passed rectally
• Reduced frequency of bowel
movements
• Oozing liquid stool
• Rectal fullness or pressure
• Rectal pain with bowel movement
• Small stool volume
• Inability to defecate

Each item rated on a 3-point scale:
• 0 = no problem
• 1 = some problem
• 2 = severe problem

Total score range: 0-16
• 0 = no constipation
• 16 = severe
constipationScore ≥1 indicates
constipation

Constipation Scoring
System169

Evaluates eight items:
• Frequency of bowel movements
• Difficult or painful evacuation
• Completeness of evacuation
• Abdominal pain
• Time per attempt
• Type of assistance (none, laxatives,
digital/enema)
• Number of unsuccessful attempts at
evacuation in a 24-h period
• Duration of constipation

Each item rated on a five-point
scale:
• 0 = none of the time
• 4 = all the timeOne item is
rated from 0 to 2

Total score range: 0-3 0
• 0 = normal
• 30 = severe
constipationScore ≥15
indicates constipation

Patient Assessment of
Constipation-Symptoms170

Evaluates 12 items with three subscales:
• Abdominal (four items)
• Rectal (three items)
• Stool (five items)

Each item rated on a 5-point scale:
• 0 = symptom absent
• 1 = mild
• 2 = moderate
• 3 = severe
• 4 = very severe

Total score range: 0-4
• Generated by dividing the
total score by the number of
questions completed
• Higher scores associated
with higher symptom burden

preferred.165 For example, apps may assist in tracking diet and the

AC K N OW L E D G E M E N T S

symptoms of IBS-C to see if there is a correlation.166 Administering

The authors thank Blair Hesp, PhD, CMPP, Julie O'Grady, BA, and

scales via an app either in the clinic or in the advance of an appoint-

Nicole Coolbaugh, CMPP, of The Medicine Group, LLC (New Hope,

ment may also optimise resource use.

PA, USA), who provided medical writing and editorial assistance,
which was funded by Salix Pharmaceuticals, Inc, in accordance with

6.6 | Summary

Good Publication Practice guidelines.
Declaration of personal interests: Dr. A. Sharma served on advisory
boards for Ironwood Pharmaceuticals, Phathom Pharmaceuticals

CIC and IBS-C are historically classified as idiopathic; however,

and Salix Pharmaceuticals. Dr. S. S. C. Rao has served on the ad-

pathophysiological dysfunctions can be commonly identified in

visory board for Medtronic, Takeda Pharmaceuticals and Salix

these constipation disorders, which could aid effective manage-

Pharmaceuticals. K. Kearns has served as a speaker for Medtronic

ment. In addition, pelvic floor disorders such as dyssynergic def-

and Takeda Pharmaceuticals, and a speaker and advisory board mem-

ecation are common and often may present with overlapping

ber for Salix Pharmaceuticals. K. D. Orleck has served as a speaker

symptoms of infrequent defecation and difficulty with defecation.

for AbbVie Pharmaceuticals, Allergan Pharmaceuticals and Salix

Gastroenterology providers should be familiar with the constipa-

Pharmaceuticals. Dr. S. A. Waldman has served on advisory boards

tion subtypes and their underlying pathophysiology, as well as key

for Salix Pharmaceuticals. He serves on the Board of Directors and

signalling pathways that may contribute to constipation. Although

is Chair of the Scientific Advisory Board for Targeted Diagnostics &

lifestyle and diet modifications are useful, laxatives remain the

Therapeutics, Inc.

first-line treatment of constipation. For laxative-refractory cases,
several classes of prokinetic and prosecretory agents are available.

AU T H O R S H I P

Familiarisation with the varied mechanisms of action, expected ef-

Guarantor of the article: Amol Sharma, MD.

ficacy and side effects helps to select the appropriate treatment

Author contributions: Amol Sharma, Satish S. C. Rao, Kimberly

and meet patient expectations. Treatment algorithms are available

Kearns, Kimberly D. Orleck and Scott A. Waldman made substan-

to guide decision-making. Smartphone apps can help gastroen-

tial contributions to conception and design of the manuscript,

terology providers and patients track constipation symptoms and

performed the research, were involved in the drafting of the man-

treatment response.

uscript and revising it critically for important intellectual content

|

SHARMA et al.

and provided final approval of the version to be published. All the
authors approved the final version of this manuscript, including the
authorship list.
DATA AVA I L A B I L I T Y S TAT E M E N T
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
ORCID
Amol Sharma

https://orcid.org/0000-0002-5843-1220

REFERENCES
1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic
idiopathic constipation in the community: systematic review and
meta-analysis. Am J Gastroenterol. 2011;106:1582-1591.
2. Rao SS, Camilleri M. Approach to the patient with constipation. In:
Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang
TC, eds. Yamada's Textbook of Gastroenterology. Hoboken, NJ:
Wiley; 2015:757-780.
3. Serra J, Mascort-Roca J, Marzo-C astillejo M, et al. Clinical practice guidelines for the management of constipation in adults. Part
1: definition, aetiology and clinical manifestations. Gastroenterol
Hepatol. 2017;40:132-141.
4. Sharma A, Rao S. Constipation: pathophysiology and current therapeutic approaches. Handb Exp Pharmacol. 2017;239:59-74.
5. Basilisco G, Coletta M. Chronic constipation: a critical review. Dig
Liver Dis. 2013;45:886-893.
6. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25:16b-21b.
7. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25:599-608.
8. Bellini M, Usai-Satta P, Bove A, et al. Chronic constipation diagnosis and treatment evaluation: the "CHRO.CO.DI.T.E." study. BMC
Gastroenterol. 2017;17:11.
9. Chey WD. Symposium report: an evidence-based approach to
IBS and CIC: applying new advances to daily practice: a review
of an adjunct clinical symposium of the American College of
Gastroenterology Meeting October 16, 2016 * Las Vegas, Nevada.
Gastroenterol Hepatol. 2017;13:1-16.
10. Allen-Brady K, Tuteja AK. Chapter 33 -Opioid-induced bowel disorder and narcotic bowel syndrome. In: Rao SSC, Lee YY, Ghoshal
UC, eds. Clinical and Basic Neurogastroenterology and Motility.
Cambridge, MA: Academic Press; 2020:463-475.
11. Bharucha AE, Dorn SD, Lembo A, Pressman A. American
Gastroenterological Association medical position statement on
constipation. Gastroenterology. 2013;144:211-217.
12. Sharma A, Rao S, Harrison JH. Anorectal function. Encyclopedia
of Gastroenterology. 2nd edn. Vol. 1. Oxford: Academic Press;
2020:99-104.
13. Patcharatrakul T, Rao SSC. Update on the pathophysiology and
management of anorectal disorders. Gut Liv. 2018;12:375-384.
14. Rao SS. Dyssynergic defecation. Gastroenterol Clin North Am.
2001;30:97-114.
15. Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel
M. Methane on breath testing is associated with constipation: a systematic review and meta-a nalysis. Dig Dis Sci.
2011;56:1612-1618.
16. Wolf PG, Parthasarathy G, Chen J, et al. Assessing the colonic
microbiome, hydrogenogenic and hydrogenotrophic genes, transit and breath methane in constipation. Neurogastroenterol Motil.
2017;29:1-9.

1263

17. Attaluri A, Jackson M, Valestin J, Rao SS. Methanogenic flora is associated with altered colonic transit but not stool characteristics in
constipation without IBS. Am J Gastroenterol. 2010;105:1407-1411.
18. Camilleri M, Ford AC. Irritable bowel syndrome: pathophysiology and current therapeutic approaches. Handb Exp Pharmacol.
2017;239:75-113.
19. Rao SSC, Xiang X, Yan Y, et al. Randomised clinical trial: linaclotide
vs placebo—a study of bi-directional gut and brain axis. Aliment
Pharmacol Ther. 2020;51:1332-1341.
20. Ghoshal U, Shukla R, Srivastava D, Ghoshal UC. Irritable bowel
syndrome, particularly the constipation-predominant form, involves an increase in Methanobrevibacter smithii, which is associated with higher methane production. Gut Liv. 2016;10:932-938.
21. Andresen V, Banerji V, Hall G, Lass A, Emmanuel AV. The patient
burden of opioid-induced constipation: new insights from a large,
multinational survey in five European countries. United European
Gastroenterol J. 2018;6:1254-1266.
22. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson
R. The prevalence, severity, and impact of opioid-induced bowel
dysfunction: results of a US and European Patient Survey (PROBE
1). Pain Med. 2009;10:35-42.
23. Rao SS, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol
Hepatol. 2016;13:295-3 05.
24. Bharucha AE, Pemberton JH, Locke GR 3rd. American
Gastroenterological Association technical review on constipation.
Gastroenterology. 2013;144:218-238.
25. Yan Y, Jimenez E, Sharma A, et al. Sa1728 How useful is
Constipation Stool APP compared to paper stool diary - randomized study of constipation and healthy subjects. Gastroenterology.
2020;158:S-4 00.
26. Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol.
2012;5:233-247.
27. Rao SSC. Plecanatide: a new guanylate cyclase agonist for
the treatment of chronic idiopathic constipation. Therap Adv
Gastroenterol. 2018;11:1756284818777945.
28. Mearin F, Ciriza C, Mínguez M, et al. Clinical Practice Guideline:
Irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108:332-363.
29. Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat
Rev Dis Primers. 2017;3:17095.
30. Sharma A, Kurek J, Morgan JC, Wakade C, Rao SSC. Constipation
in Parkinson's disease: a nuisance or nuanced answer to the pathophysiological puzzle? Curr Gastroenterol Rep. 2018;20:1.
31. Lee YY, Haque M, Lawenko R, Sharma A. Systemic disorders that affect gastrointestinal motility. Clinical and Basic Neurogastroenterology
and Motility. Cambridge, MA: Academic Press; 2020:601-618.
32. Serra J, Mascort-Roca J, Marzo-C astillejo M, et al. Clinical practice
guidelines for the management of constipation in adults. Part 2:
diagnosis and treatment. Gastroenterol Hepatol. 2017;40:303-316.
33. Tantiphlachiva K, Rao P, Attaluri A, Rao SS. Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin
Gastroenterol Hepatol. 2010;8:955-960.
34. Rao SSC. Rectal exam: yes, it can and should be done in a busy
practice! Am J Gastroenterol. 2018;113:635-638.
35. Carrington EV, Scott SM, Bharucha A, et al. Expert consensus document: advances in the evaluation of anorectal function. Nat Rev
Gastroenterol Hepatol. 2018;15:309-323.
36. Carrington EV, Heinrich H, Knowles CH, et al. The international
anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. Neurogastroenterol Motil.
2020;32:e13679.

1264

|

37. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the
balloon expulsion test for excluding the diagnosis of pelvic floor
dyssynergia in constipation. Gastroenterology. 2004;126:57-62.
38. Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. Gastroenterology. 2006;130:1510-1518.
39. Kang HR, Lee JE, Lee JS, et al. Comparison of high-resolution anorectal manometry with water-perfused anorectal manometry. J
Neurogastroenterol Motil. 2015;21:126-132.
40. Rao SS, Azpiroz F, Diamant N, Enck P, Tougas G, Wald A. Minimum
standards of anorectal manometry. Neurogastroenterol Motil.
2002;14:553-559.
41. Rao SS. Dyssynergic defecation and biofeedback therapy.
Gastroenterol Clin North Am. 2008;37:569-586, viii.
42. Sharif H, Devadason D, Abrehart N, Stevenson R, Marciani L.
Imaging measurement of whole gut transit time in paediatric and
adult functional gastrointestinal disorders: a systematic review
and narrative synthesis. Diagnostics. 2019;9:221.
43. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology.
2016;150:1393-1407.e5.
44. Lee YY, Erdogan A, Rao SS. How to assess regional and whole gut
transit time with wireless motility capsule. J Neurogastroenterol
Motil. 2014;20:265-270.
45. Rao SSC, Kuo B, McCallum RW, et al. Investigation of colonic
and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol.
2009;7:537-544.
46. Rao SSC, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American
and European Neurogastroenterology and Motility Societies.
Neurogastroenterol Motil. 2011;23:8-23.
47. Wang YT, Mohammed SD, Farmer AD, et al. Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the
wireless motility capsule: influence of age, gender, study country
and testing protocol. Aliment Pharmacol Ther. 2015;42:761-772.
48. Singh S, Heady S, Coss-Adame E, Rao SS. Clinical utility of colonic
manometry in slow transit constipation. Neurogastroenterol Motil.
2013;25:487-495.
49. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J
Gastroenterol. 2002;97:1910-1915.
50. Serra J, Pohl D, Azpiroz F, et al. European Society of
Neurogastroenterology and Motility guidelines on functional constipation in adults. Neurogastroenterol Motil. 2020;32:e13762.
51. Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS. Randomised
clinical trial: dried plums (prunes) vs. psyllium for constipation.
Aliment Pharmacol Ther. 2011;33:822-828.
52. Erdogan A, Rao SSC, Thiruvaiyaru D, et al. Randomised clinical
trial: mixed soluble/insoluble fibre vs. psyllium for chronic constipation. Aliment Pharmacol Ther. 2016;44:35-4 4.
53. Chey SW, Chey WD, Jackson K, Eswaran S. S0454 Randomized,
comparative effectiveness trial of green kiwifruit, psyllium,
or prunes in U.S. patients with chronic constipation. Am J
Gastroenterol. 2020;115:S229.
54. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and
meta-analysis. Gut. 2011;60:209-218.
55. Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy,
safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the
treatment of functional chronic constipation. Gut. 2000;46:
522-526.
56. Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J
Gastroenterol. 2007;102:1436-1441.

SHARMA et al.

57. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic
polyethylene glycol electrolyte balanced solution (PMF-100)
in treatment of chronic nonorganic constipation. Dig Dis Sci.
1996;41:1636-1642.
58. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose
versus polyethylene glycol for chronic constipation. Cochrane
Database Syst Rev. 2010;(7):Cd007570.
59. Belsey JD, Geraint M, Dixon TA. Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation.
Int J Clin Pract. 2010;64:944-955.
60. Awad RA, Camacho S. A randomized, double-blind, placebo-
controlled trial of polyethylene glycol effects on fasting and
postprandial rectal sensitivity and symptoms in hypersensitive
constipation-predominant irritable bowel syndrome. Colorectal
Dis. 2010;12:1131-1138.
61. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized
clinical trial: macrogol/PEG 3350 plus electrolytes for treatment
of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108:1508-1515.
62. Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R,
Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol.
2011;9:577-583.
63. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA.
Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study.
Aliment Pharmacol Ther. 2006;23:1479-1488.
64. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week,
double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol.
2010;105:897-903.
65. Brancale A, Shailubhai K, Ferla S, Ricci A, Bassetto M, Jacob GS.
Therapeutically targeting guanylate cyclase-C: computational
modeling of plecanatide, a uroguanylin analog. Pharmacol Res
Perspect. 2017;5:e00295.
66. Islam BN, Sharman SK, Browning DD. Clinical utility of plecanatide
in the treatment of chronic idiopathic constipation. Int J Gen Med.
2018;11:323-330.
67. Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic
target in gastrointestinal disorders. Gut. 2018;67:1543-1552.
68. Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-
Santiago I. Guanylate cyclase-C/cGMP: an emerging pathway in
the regulation of visceral pain. Front Mol Neurosci. 2014;7:31.
69. Waldman SA, Tenenbaum R, Foehl HC, Winkle P, Griffin P. Blunted
evoked prouroguanylin endocrine secretion in chronic constipation. Clin Transl Gastroenterol. 2019;10:e00016.
70. Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a
systematic review and meta-analysis. Neurogastroenterol Motil.
2014;26:499-509.
71. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with
constipation: results of two phase 3 randomized clinical trials. Am
J Gastroenterol. 2018;113:735-745.
72. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel
syndrome with constipation: a 26-week, randomized, double-
blind, placebo-controlled trial to evaluate efficacy and safety. Am J
Gastroenterol. 2012;107:1702-1712.
73. DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P.
Randomized clinical trial: efficacy and safety of plecanatide in
the treatment of chronic idiopathic constipation. Therap Adv
Gastroenterol. 2017;10:837-851.
74. Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in chronic idiopathic
constipation patients with moderate to severe abdominal bloating:
a randomized, controlled trial. PLoS One. 2015;10:e0134349.

|

SHARMA et al.

75. Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology.
2010;138:886-895.e1.
76. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527-536.
77. Miner PB, Koltun WD, Wiener GJ, et al. A randomized phase
III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol.
2017;112:613-621.
78. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled
trial with a 4-week randomized withdrawal period to evaluate
the efficacy and safety of linaclotide in irritable bowel syndrome
with constipation. Am J Gastroenterol. 2012;107:1714-1724; quiz
p.1725.
79. Schoenfeld P, Lacy BE, Chey WD, et al. Low-dose linaclotide
(72μg) for chronic idiopathic constipation: a 12-week, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol.
2018;113:105-114.
80. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients
with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1084-
1092.e3; quiz e68.
81. Yang Y, Fang J, Guo X, et al. Linaclotide in irritable bowel syndrome
with constipation: a Phase 3 randomized trial in China and other
regions. J Gastroenterol Hepatol. 2018;33:980-989.
82. Fukudo S, Miwa H, Nakajima A, et al. A randomized controlled
and long-term linaclotide study of irritable bowel syndrome
with constipation patients in Japan. Neurogastroenterol Motil.
2018;30:e13444.
83. Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials:
linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Aliment Pharmacol Ther. 2013;37:49-61.
84. Barish CF, Crozier RA, Griffin PH. Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel
syndrome with constipation. Curr Med Res Opin. 2019;35:81-85.
85. Barish CF, Griffin P. Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence
from an open-label study. Curr Med Res Opin. 2018;34:751-755.
86. Griffin PH. ,Comment on meta analysis by Shah et al. Am J
Gastroenterol. 2018;113:1395.
87. Niewinna K, Zielinska A, Fichna J. Recent advances in the pharmacological management of constipation predominant irritable bowel
syndrome. Expert Opin Pharmacother. 2020;21:73-8 4.
88. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA.
Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.
Gastroenterology. 2006;130:34-43.
89. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of
5-hydroxytryptamine metabolism in irritable bowel syndrome.
Clin Gastroenterol Hepatol. 2005;3:349-357.
90. Bonfiglio F, Liu X, Smillie C, et al. GWAS of stool frequency reveals genes, pathways, and cell types relevant to human gastrointestinal motility and irritable bowel syndrome. medRxiv.
2020:2020.2006.2017.20132555.
91. El-Salhy M, Norrgard O, Spinnell S. Abnormal colonic endocrine
cells in patients with chronic idiopathic slow-transit constipation.
Scand J Gastroenterol. 1999;34:1007-1011.
92. Jiang C, Xu Q, Wen X, Sun H. Current developments in pharmacological therapeutics for chronic constipation. Acta pharmaceutica
Sinica B. 2015;5:300-3 09.
93. Prichard DO, Bharucha AE. Recent advances in understanding and
managing chronic constipation. F1000Res. 2018;7:1640.
94. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S,
Zinsmeister AR. Prucalopride accelerates gastrointestinal and

95.
96.

97.

98.

99.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

1265

colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354-360.
In brief: Tegaserod (Zelnorm) returns. Med Lett Drugs Ther.
2019;61:72.
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-
controlled trial of prucalopride for severe chronic constipation. N
Engl J Med. 2008;358:2344-2354.
Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial:
the efficacy, impact on quality of life, and safety and tolerability of
prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol
Ther. 2009;29:315-328.
Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L.
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357-365.
Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P,
Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up
of patients from the pivotal studies. Aliment Pharmacol Ther.
2010;32:1113-1123.
Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and
safety of prucalopride in chronic constipation: an integrated
analysis of six randomized, controlled clinical trials. Dig Dis Sci.
2016;61:2357-2372.
Sajid MS, Hebbar M, Baig MK, Li A, Philipose Z. Use of prucalopride
for chronic constipation: a systematic review and meta-analysis of
published randomized, controlled trials. J Neurogastroenterol Motil.
2016;22:412-422.
Tack J, Quigley E, Camilleri M, Vandeplassche L, Kerstens R.
Efficacy and safety of oral prucalopride in women with chronic
constipation in whom laxatives have failed: an integrated analysis.
United European Gastroenterol J. 2013;1:48-59.
Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in
treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J
Gastroenterol. 2020;115:281-293.
Eswaran S, Guentner A, Chey WD. Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and
chronic constipation. J Neurogastroenterol Motil. 2014;20:141-151.
Abrahamsson H, Ostlund-Lindqvist AM, Nilsson R, Simren
M, Gillberg PG. Altered bile acid metabolism in patients with
constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol. 2008;43:1483-1488.
Bazzoli F, Malavolti M, Petronelli A, Barbara L, Roda E. Treatment
of constipation with chenodeoxycholic acid. J Int Med Res.
1983;11:120-123.
Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females
with irritable bowel syndrome-constipation: a pharmacodynamic
and pharmacogenetic analysis. Gastroenterology. 2010;139:1549-
1558, 1558.e1.
Chey WD, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid
transporter inhibitor, for chronic idiopathic constipation. Am J
Gastroenterol. 2011;106:1803-1812.
Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of
elobixibat for chronic constipation: results from a randomised,
double-blind, placebo-controlled, phase 3 trial and an open-
label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol.
2018;3:537-547.
Kumagai Y, Amano H, Sasaki Y, et al. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor,
on chronic constipation: a randomized controlled trial. Br J Clin
Pharmacol. 2018;84:2393-2404.
Nakajima A, Seki M, Taniguchi S. Determining an optimal clinical
dose of elobixibat, a novel inhibitor of the ileal bile acid transporter,

1266

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

|
in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
J Gastroenterol. 2018;53:525-534.
Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin
EP receptors by lubiprostone in rat and human stomach and colon.
Br J Pharmacol. 2008;154:126-135.
Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB Jr, Ueno
R. Long-term safety and effectiveness of lubiprostone, a chloride
channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011;56:2639-2645.
Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week,
double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients
with chronic constipation. Am J Gastroenterol. 2008;103:170-177.
Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical
trial: phase 2 study of lubiprostone for irritable bowel syndrome
with constipation. Aliment Pharmacol Ther. 2008;27:685-696.
Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety
of lubiprostone in patients with chronic constipation. Dig Dis Sci.
2010;55:1090-1097.
Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno
R. Safety and patient outcomes with lubiprostone for up to 52
weeks in patients with irritable bowel syndrome with constipation.
Aliment Pharmacol Ther. 2012;35:587-599.
Li F, Fu T, Tong W-D, et al. Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome. Mayo Clin Proc. 2016;91:456-468.
Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of
oral lubiprostone in constipated patients with or without irritable
bowel syndrome: a randomized, placebo-controlled and dose-
finding study. Neurogastroenterol Motil. 2011;23:544-e205.
Fukudo S, Hongo M, Kaneko H, Takano M, Ueno R. Lubiprostone
increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin
Gastroenterol Hepatol. 2015;13:294-3 01.e5.
Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel
syndrome–results of two randomized, placebo-controlled studies.
Aliment Pharmacol Ther. 2009;29:329-3 41.
Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-
blind, placebo-controlled, dose-ranging study to evaluate efficacy
and safety. Aliment Pharmacol Ther. 2007;25:1351-1361.
Rao SSC, Lichtlen P, Habibi S. Effects of lubiprostone, an intestinal secretagogue, on electrolyte homeostasis in chronic idiopathic
and opioid-induced constipation. J Clin Gastroenterol. 2020;32(11).
Publish Ahead of Print. https://doi.org/10.1097/MCG.00000
000000 01385
Leppert W. The role of opioid receptor antagonists in the
treatment of opioid-induced constipation: a review. Adv Ther.
2010;27:714-730.
Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain. 2019;35:174-188.
Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson
BJ, Sultan S. American Gastroenterological Association Institute
Guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156:218-226.
Vijayvargiya P, Camilleri M, Vijayvargiya P, Erwin P, Murad MH.
Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. Aliment Pharmacol Ther.
2020;52:37-53.
Rao SS, Benninga MA, Bharucha AE, Chiarioni G, Di Lorenzo
C, Whitehead WE. ANMS-ESNM position paper and

SHARMA et al.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

consensus guidelines on biofeedback therapy for anorectal disorders. Neurogastroenterol Motil. 2015;27:594-609.
Rao SSC, Seaton K, Miller M, et al. Randomized controlled trial of
biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5:331-338.
Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead
WE. Randomized, controlled trial shows biofeedback to be superior
to alternative treatments for patients with pelvic floor dyssynergia-
type constipation. Dis Colon Rectum. 2007;50:428-4 41.
Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G.
Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology.
2006;130:657-664.
Rao SSC, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-
term efficacy of biofeedback therapy for dyssynergic defecation:
randomized controlled trial. Am J Gastroenterol. 2010;105:890-896.
Lee HJ, Boo SJ, Jung KW, et al. Long-term efficacy of biofeedback
therapy in patients with dyssynergic defecation: results of a median
44 months follow-up. Neurogastroenterol Motil. 2015;27:787-795.
Patcharatrakul T, Gonlachanvit S. Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable
bowel syndrome. J Clin Gastroenterol. 2011;45:593-598.
Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits
only patients with outlet dysfunction, not patients with isolated
slow transit constipation. Gastroenterology. 2005;129:86-97.
Shin JK, Cheon JH, Kim ES, et al. Predictive capability of anorectal physiologic tests for unfavorable outcomes following biofeedback therapy in dyssynergic defecation. J Korean Med Sci.
2010;25:1060-1065.
Rao SSC, Valestin JA, Xiang X, Hamdy S, Bradley CS, Zimmerman
MB. Home-based versus office-based biofeedback therapy for
constipation with dyssynergic defecation: a randomised controlled
trial. Lancet Gastroenterol Hepatol. 2018;3:768-777.
Rao SSC, Go JT, Valestin J, Schneider J. Home biofeedback for the
treatment of dyssynergic defecation: does it improve quality of life
and is it cost-effective? Am J Gastroenterol. 2019;114:938-944.
Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC.
Efficacy of drugs in chronic idiopathic constipation: a systematic
review and network meta-analysis. Lancet Gastroenterol Hepatol.
2019;4:831-8 44.
Tse Y, Armstrong D, Andrews CN, et al. Treatment algorithm for
chronic idiopathic constipation and constipation-predominant irritable bowel syndrome derived from a Canadian national survey
and needs assessment on choices of therapeutic agents. Can J
Gastroenterol Hepatol. 2017;2017:8612189.
Harris LA, Horn J, Kissous-Hunt M, Magnus L, Quigley EMM.
The Better Understanding and Recognition of the Disconnects,
Experiences, and Needs of patients with Chronic Idiopathic
Constipation (BURDEN-CIC) study: results of an online questionnaire. Adv Ther. 2017;34:2661-2673.
Soufi-Afshar I, Moghadamnia A, Bijani A, Kazemi S, Shokri-
Shirvani J. Comparison of pyridostigmine and bisacodyl in the
treatment of refractory chronic constipation. Caspian J Intern Med.
2016;7:19-24.
Bharucha AE, Low PA, Camilleri M, Burton D, Gehrking TL,
Zinsmeister AR. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res.
2008;18:194-202.
Bharucha AE, Low P, Camilleri M, et al. A randomised controlled
study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut.
2013;62:708-715.
Rao SSC, Lembo A, Chey WD, Friedenberg K, Quigley EMM. Effects
of the vibrating capsule on colonic circadian rhythm and bowel

|

SHARMA et al.

146.

147.

148.
149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

symptoms in chronic idiopathic constipation. Neurogastroenterol
Motil. 2020;32:e13890.
NICE Guidance: Irritable bowel syndrome in adults: diagnosis and
management. 2008. https://www.nice.org.uk/guidance/cg61.
Date Accessed: March 10, 2020.
Hussain ZH, Everhart K, Lacy BE. Treatment of chronic constipation: prescription medications and surgical therapies. Gastroenterol
Hepatol. 2015;11:104-114.
Griffiths DM, Malone PS. The Malone antegrade continence
enema. J Pediatr Surg. 1995;30:68-71.
Lees NP, Hodson P, Hill J, Pearson RC, MacLennan I. Long-term results of the antegrade continent enema procedure for constipation
in adults. Colorectal Dis. 2004;6:362-368.
Portier G, Ghouti L, Kirzin S, Chauffour M, Lazorthes F. Malone
antegrade colonic irrigation: ileal neoappendicostomy is the preferred procedure in adults. Int J Colorectal Dis. 2006;21:458-460.
Teichman JM, Zabihi N, Kraus SR, Harris JM, Barber DB. Long-
term results for Malone antegrade continence enema for adults
with neurogenic bowel disease. Urology. 2003;61:502-506.
Meurette G, Lehur PA, Coron E, Regenet N. Long-term results of
Malone's procedure with antegrade irrigation for severe chronic
constipation. Gastroenterol Clin Biol. 2010;34:209-212.
Duchalais E, Meurette G, Mantoo SK, et al. Percutaneous endoscopic caecostomy for severe constipation in adults: feasibility,
durability, functional and quality of life results at 1 year follow-up.
Surg Endosc. 2015;29:620-626.
Uno Y. Introducer method of percutaneous endoscopic cecostomy
and antegrade continence enema by use of the Chait Trapdoor
cecostomy catheter in patients with adult neurogenic bowel.
Gastrointest Endosc. 2006;63:666-673.
Gerharz EW, Vik V, Webb G, Leaver R, Shah PJ, Woodhouse CR.
The value of the MACE (Malone antegrade colonic enema) procedure in adult patients. J Am Coll Surg. 1997;185:544-547.
Biyani D, Barrow E, Hodson P, Watson AJ, Maclennan I.
Endoscopically placed caecostomy buttons: a trial ACE procedure.
Colorectal Dis. 2007;9:373-376.
Hirst GR, Arumugam PJ, Watkins AJ, et al. Antegrade continence
enema in the treatment of obstructed defaecation with or without
faecal incontinence. Tech Coloproctol. 2005;9:217-221.
Altomare DF, Rinaldi M, Rubini D, et al. Long-term functional assessment of antegrade colonic enema for combined incontinence
and constipation using a modified Marsh and Kiff technique. Dis
Colon Rectum. 2007;50:1023-1031.
Poirier M, Abcarian H, Nelson R. Malone antegrade continent
enema: an alternative to resection in severe defecation disorders.
Dis Colon Rectum. 2007;50:22-28.

1267

160. Worsoe J, Christensen P, Krogh K, Buntzen S, Laurberg S. Long-
term results of antegrade colonic enema in adult patients: assessment of functional results. Dis Colon Rectum. 2008;51:1523-1528.
161. Whiteley I, Stewart P. Antegrade continence enema (ACE) in
adults: a review of long-term outcomes and complications from a
single institution. Aust N Z Continence J. 2020;26.
162. Chan DS, Delicata RJ. Meta-analysis of antegrade continence
enema in adults with faecal incontinence and constipation. Br J
Surg. 2016;103:322-327.
163. Rao SSC, Seaton K, Miller MJ, et al. Psychological profiles and
quality of life differ between patients with dyssynergia and those
with slow transit constipation. J Psychosom Res. 2007;63:441-4 49.
164. Almario CV, Spiegel BMR. Employing irritable bowel syndrome patient-reported outcomes in the clinical trenches. Clin
Gastroenterol Hepatol. 2018;16:462-466.e2.
165. Yan Y, Karunaratne T, Jimenez E, et al. Electronic APP vs. paper
form stool diary for fecal incontinence: 2877. Am J Gastroenterol.
2019;114:S1577–S1578. (2019 ACG Annual Meeting Abstracts).
166. Zia J, Schroeder J, Munson S, et al. Feasibility and usability pilot
study of a novel irritable bowel syndrome food and gastrointestinal symptom journal smartphone app. Clin Transl Gastroenterol.
2016;7:e147.
167. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in
chronic constipation: a randomized, double-blind, controlled trial.
Clin Gastroenterol Hepatol. 2004;2:796-8 05.
168. Sharma S, Agarwal B. Scoring systems in evaluation of constipation and obstructed defecation syndrome (ODS). J Int Med Sci
Acad. 2012;25:57-59.
169. McCrea HJ, Ment LR. The dianeonategnosis, management,
and postnatal prevention of intraventricular hemorrhage in the
preterm. Clin Perinatol. 2008;35:777-792, vii.
170. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric
validation of a constipation symptom assessment questionnaire.
Scand J Gastroenterol. 1999;34:870-877.
171. Simrén M, Tack J. New treatments and therapeutic targets for
IBS and other functional bowel disorders. Nat Rev Gastroenterol
Hepatol. 2018;15:589-605.

How to cite this article: Sharma A, Rao SSC, Kearns K, Orleck
KD, Waldman SA. Review article: diagnosis, management and
patient perspectives of the spectrum of constipation disorders.
Aliment Pharmacol Ther. 2021;53:1250–1267. https://doi.
org/10.1111/apt.16369

